Latest Conference Coverage

Elevating Patient Perspectives in the Mangement of Parkinson Disease: Esther Labib-Kiyarash, MSHA, CPHQ

At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]

Exploring Orexin Neuron Loss as an Early Driver of Sleep Disturbances in Alzheimer Disease

Lea Grinberg, MD, PhD, a neuropathologist at Mayo Clinic Florida, discussed how tau accumulation and orexin neuron loss drive early sleep disturbances in Alzheimer disease and the potential for sleep-based biomarkers.

Achieving Consensus Definitions for Refractory and Resistant Migraine: Jennifer Robblee, MD, MSc

The headache neurologist at the Barrow Neurological Institute talked about an international expert panel that established agreed-upon definitions for refractory and resistant migraine. [WATCH TIME: 4 minutes]

Insights on Safety and Clinical Guidance for Cannabinoid Use in Migraine: Nathaniel M. Schuster, MD

At AHS 2025, the associate clinic director at the UC San Diego talked about the cautious use of cannabinoids in migraine and the importance of standard therapies before cannabinoids. [WATCH TIME: 3 minutes]

Exploring Adenosine A3 as a Novel Target for Trigeminal Neuropathic Pain: Marcela Romero-Reyes, DDS, PhD, FAHS

The director of the Brotman Facial Pain Clinic at the University of Maryland talked about emerging preclinical evidence supporting adenosine A3 receptor activation for post-traumatic trigeminal neuropathic pain. [WATCH TIME: 5 minutes]

Analyzing How Sex and Age May Influence Risk of Stroke in Veterans With Migraine

At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.

Overviewing the Role of Amyloid-ß Oligomers and Valiltramiprosate in Alzheimer Disease: John Hey, PhD

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

Key Considerations in the Use of On-Demand Therapy for Parkinson OFF Episodes: Cheryl Kyinn, PA-C

The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]

The Growing Care Impact of Speech and Physical Therapy in Parkinson Disease: Cynthia Fox, PhD, CCC-SLP

The CEO and cofounder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]

Evaluating the VeraBIND Tau Assay for Earlier Detection of Alzheimer Disease: John Forrest

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]

Expanding the Presence of the ALZpath Blood Test in Alzheimer Disease Research: Mike Banville

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]

AAIC 2025 Preclinical Results of Anti-Tau Antibody MK-2214 in Alzheimer Disease: Jonathan Sugam, PhD

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

Building Empathy Through Patient-Centered Simulations: Perspectives From 2025 ATMRD Congress

At the 2025 ATMRD Congress, Anissa Mitchell, LCSW, chief program officer at PMD Alliance, discussed immersive, patient-focused sessions aimed at improving clinicians’ empathy, communication, and understanding of Parkinson disease and related disorders.

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

The medical director of CNS clinical cevelopment at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b trial assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the sleep disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Evaluating Biomarkers to Guide Personalized Remyelination Strategies in MS: Ahmed Abdelhak, MD

At CMSC 2025, assistant professor of neurology at the University of California, San Francisco discussed progress on the integration of biomarkers into clinical practice for multiple sclerosis. [WATCH TIME: 4 minutes]

Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.

Higher Levels of Postpartum Depression in Women With MS Raise Importance for Screening Efforts

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.

Reducing Sodium in Narcolepsy Treatment: Cardiovascular Insights From the XYLO Trial

Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.

Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

NeuroVoices: Howard Fillit, MD, on AAIC 2025 Highlights in Alzheimer Disease Prevention, Biomarkers, and Therapeutics

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer disease field presented at the 2025 Alzheimer’s Association International Conference.

Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025.

AAIC 2025: Top Interviews and Key Takeaways

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.

Larger, More Controlled Studies Needed to Confirm Genistein’s Potential to Curve Alzheimer Cognition

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer disease, urging further research for validation.

Importance of Patient Selection and Future Therapies in Alzheimer Treatment

In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.

Real-World Analysis Shows Growing Use of Octave’s MS Disease Activity Test in Clinical Practice

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Maintaining Efficacy in Safer Donanemab Dosing Regimen

Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.

Alzheimer Psychosis Agent ACP-204 Shows No Impact on Corrected QT Intervals in Phase 1 Analysis

New findings reveal ACP-204 shows no significant QT interval prolongation in healthy adults, supporting its safety for Alzheimer disease psychosis treatment.

Donanemab Dosing and ARIA Risk in TRAILBLAZER-ALZ 6

Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.

Monitoring Long-Term Efficacy of Migraine Wearable Device Over 3 Years: Alit Stark-Inbar, PhD

The corporate vice president of medical information and research at Theranica discussed long-term findings presented at AHS 2025 covering the company’s Nerivio remote electrical neuromodulation device for patients with migraine. [WATCH TIME: 5 minutes]